Provectus Biopharmaceuticals Inc.’ PV-10 Clinical Data On The Treatment Of Melanoma To Be Presented At 10th European Association Of Dermato-Oncology Congress
4/21/2014 6:20:41 AM
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus’ PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania.
Help employers find you! Check out all the jobs and post your resume.
comments powered by